Ads
related to: oxybutynin dosage for hyperhidrosis disease mayo clinic treatment for copdconsumereview.org has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Since the 2010s, oxybutynin has increasingly been used to treat hyperhidrosis (excessive sweating). [15] [16] Numerous studies have identified concrete benefits of the drug in treating this condition, but have not identified appropriate dosing or the full spectrum of possible side effects, although dry mouth is seemingly infrequent in patients with hyperhidrosis.
It has been used topically and orally to treat hyperhidrosis, in particular, gustatory hyperhidrosis and generalized hyperhidrosis. [20] [21] When inhaled, it is used to treat chronic obstructive pulmonary disease (COPD). [4] [5] [6] Doses for inhalation are much lower than oral ones, so that swallowing a dose will not have an effect. [22] [23]
Hyperhidrosis is a medical condition in which a person exhibits excessive sweating, [1] [2] more than is required for the regulation of body temperature. [3] Although it is primarily a physical burden, hyperhidrosis can deteriorate the quality of life of the people who are affected from a psychological, emotional, and social perspective. [4]
In 1900, Reid Hunt, a pharmacologist (1870-1948), realised a fall in blood pressure in rabbits after removing adrenaline (epinephrine) from adrenal glands extract. While he initially attributed this effect to choline, he later discovered acetylcholine was 100 000 times more potent in lowering blood pressure.
Endoscopic thoracic sympathectomy (ETS) is a surgical procedure in which a portion of the sympathetic nerve trunk in the thoracic region is destroyed. [1] [2] ETS is used to treat excessive sweating in certain parts of the body (focal hyperhidrosis), facial flushing, Raynaud's disease and reflex sympathetic dystrophy.
Focal hyperhidrosis, also known as primary hyperhidrosis, is a disease characterized by an excessive sweating localized in certain body regions (particularly palms, feet and underarms). Studies suggest that this condition, affecting between 1% and 3% of the US population, seems to have a genetic predisposition in about two thirds of those affected.